Nachrichten zur Viatris Inc. Aktie

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

…

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

…

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent By Reuters

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent…

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company…

Viatris Stock Is Still Worth Buying

…

Global Pregabalin Market Size To Worth USD 2.18 Billion By 2033 | CAGR of 2.82%

The Global Pregabalin Market Size was Valued at USD 1.65 Billion in 2023 and the Worldwide Pregabalin Market Size is…

Viatris Inc. (VTRS) R&D Event (Transcript)

…

Viatris Inc. (VTRS) Q4 2023 Earnings Call Transcript

…

Viatris reports upbeat 2024 revenue outlook By Investing.com

Viatris reports upbeat 2024 revenue outlook…

Viatris Inc. (VTRS) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

…

VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Regeneron Gains After Eye-Drug Patent Victory Over Viatris

Regeneron Pharmaceuticals Inc. rose the most since August after a court ruled that the drugmaker’s patent rights were infringed by…

Regeneron surges after patent case ruling against Viatris By Investing.com

Regeneron surges after patent case ruling against Viatris…

Kurs der Viatris-Aktie verharrt auf Vortags-Niveau (8,32081 €)

CODE Das Papier notiert zur Stunde bei 9,14 US-Dollar. Kaum auffällig ist derzeit am Aktienmarkt der Kurs von Viatris. Das…

Viatris-Aktie: Kurs fällt ab (8,50908 €)

Im US-amerikanischen Wertpapierhandel liegt der Anteilsschein von Viatris zur Stunde im Minus. Der jüngste Kurs betrug 9,32 US-Dollar. Am Aktienmarkt…

Analyst Report: Viatris Inc

…

Viatris Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Viatris Inc. (VTRS) Q3 2023 Earnings Conference Call Transcript

…

Viatris-Aktie leicht im Minus (8,91294 €)

An der US-amerikanischen Börse liegt die Viatris-Aktie derzeit im Minus. Zuletzt zahlten Investoren für die Aktie 9,37 US-Dollar. Am US-amerikanischen…

: Viatris and Ocuphire Pharma get FDA green light for eye treatment

Viatris Inc. VTRS and Ocuphire Pharma Inc. OCUP said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi…

Specialty Generics Market to Reach USD 184.8 Billion by 2032; Increasing Capacity for Walking & Physical Activities to Propel Growth, says The Brainy Insights

Global specialty generics market size from USD 70.0 billion in 2022 to USD 184.8 billion, growing at a CAGR of…

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris

One of these high-yield pharma stocks stands out as a better buy right now....…

Viatris goes ex-dividend today

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris 2022 Sustainability Report: Driving Access

NORTHAMPTON, MA / ACCESSWIRE / August 23, 2023 / ViatrisDriving Access with Generic MedicinesCompetition from generic and biosimilar medicines is…

InDex Pharmaceuticals Holding AB (publ) interim report January – June 2023

License agreement signed with Viatris Japan ”We are thrilled to start our collaborative journey with Viatris Japan and work together to…

XFRA : DIVIDEND/INTEREST INFORMATION - 23.08.2023 - US92556V1061

Das Instrument VIA US92556V1061 VIATRIS INC. O.N. EQUITY wird cum Dividende/Zinsen gehandelt am 22.08.2023 und ex Dividende/Zinsen am 23.08.2023 The…

Where Will Viatris Be in 5 Years?

Can this become a good growth business to invest in?...…

Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?

There are a few complicating factors that mean the generic form of the drug might not be a slam dunk....…

Biocon may list biosimilars business by 2025 first half - CEO

...By Rishika Sadam HYDERABAD, Aug 11 (Reuters) - Indian... Mittal told Reuters. Last year, Biocon acquired U.S.-based Viatris Incs......…

S&P changes outlook on Viatris to negative

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris 2022 Sustainability Report: Building Access and Better Health Through Education and Awareness

NORTHAMPTON, MA / ACCESSWIRE / August 9, 2023 / One of the biggest challenges facing patient care is a lack…

Is Viatris Stock Good for Dividend Income?

If you keep your expectations in check, it could be a great pick....…

Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter…

Form 10-Q Viatris Inc For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows

Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance....…

Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the…

Viatris beats second-quarter revenue estimates, says divestiture plans on track

...Aug 7 (Reuters) - Viatris Inc beat Wall Street estimates for second......…

Viatris multiple sclerosis therapy accepted for FDA review

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris posts first topline beat in over a year as Q2 revenue improves

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ROUNDUP: Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend

CANONSBURG (dpa-AFX) - While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its…

Form 8-K Viatris Inc For: Aug 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris, Mapi Pharma: FDA Accepts For Review NDA For GA Depot To Treat RMS

CANONSBURG (dpa-AFX) - Healthcare company Viatris Inc. (VTRS) and Mapi Pharma Ltd., a late-stage clinical development pharmaceutical company, announced Monday…

Viatris Inc. Q2 Profit Drops

CANONSBURG (dpa-AFX) - Viatris Inc. (VTRS) announced earnings for second quarter that decreased from last yearThe companys earnings totaled $264.0…

Viatris beats Q2 top and bottom line estimates; reaffirms FY23 outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP…

Viatris hopes for Q2 earnings beats amid negative YTD return

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years

If youre patient and consistent, it wont be too hard to build up a revenue stream....…

Viatris, Kindeva launch Breyna to treat asthma and COPD patients

The drug-device combination product, Breyna is claimed to be the first US Food and Drug Administration (FDA)-approved generic version of…

Viatris Announces Launch of Breyna Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People With Asthma and Chronic Obstructive Pulmonary Disease, in Partnership With Kindeva

PITTSBURGH, PA and WOODBURY, MN / ACCESSWIRE / July 31, 2023 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, and…

Viatris 2022 Sustainability Report: Partnering To End Tuberculosis

NORTHAMPTON, MA / ACCESSWIRE / July 24, 2023 / Tuberculosis (TB) is the second deadliest infectious disease, causing 1.5 million…